Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 407-416

  Niculescu Duvaz, Ion ^a   Roman, Esteban ^a   Whittaker, Steven R ^a   Friedlos, Frank ^a   Kirk, Ruth ^a   Scanlon, Ian J ^a   Davies, Lawrence C ^a   Niculescu Duvaz, Dan ^a   Marais, Richard ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,4,5 TRIMETHOXYPHENYLAMINO) 6 (3 ACETAMIDOPHENYL)PYRAZINE; 2 [3 (2 AMINOETHOXY)PHENYLAMINO] 6 (3 ACETAMIDOPHENYL)PYRAZINE; B RAF KINASE; BENZYLIDENE DERIVATIVE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; IC 50; MUTATION; STRUCTURE ACTIVITY RELATION;

ACETANILIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30444450278     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050983g     Document Type: Article

References (20)

1. Wellbrock, C.; Karasarides, M.; Marais, R. The RAF proteins take center stage. Nature Rev. Mol. Cell Biol. 2004, 5, 875-885.
2. Avruch, J.; Khokhlatchev, A,; Kyriakis, J. M.; Luo, Z.; Tzivion, G, et al. Ras activation of the Raf kinase: tyrosine kinase recruiment of the MAP kinase cascade. Recent Prog. Horm. Res. 2001, 56, 127-155.
3. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; al, e. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.
4. Tuveson, D. A,; Weber, B. L.; Herlyn, M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003, 2, 95-98,
5. Garnett, M. J.; Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 4, 313-319.
6. Chiloeches, A.; Marais, R. Mitogen-activated protein kinase cascades as therapeutic targets in cancer. Targets for cancer chemotherapy: transcription factors and other nuclear proteins; Humana Press Inc.: Totowa, 2002; pp 179-206.
7. Wood, E.; Crosby, R. M.; Dickerson, S.; Frye, S. V.; Griffin, R. et al, A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity. Anticancer Drug Des. 2001, 16, 1-6.
8. Hall-Jackson, C, A.; Eyers, P, A.; Cohen, P.; Boyle, F, T.; Hewitt, N. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol 1999, 6, 559-568.
9. Wilhelm, S. M.; Carter, C.; Tang, l. y.; Wilkie, D.; McNabola, A. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
10. Bollag, G.; Freeman, S.; Lyons, G. F.; Post, L, E. Raf pathway inhibition in oncology. Curr. Opin. Investig. Drugs 2004, 4, 1436-1441.
11. Lowinger, T. B.; Riedl, B.; Dumas, J.; Smith, R. A. Design and discovery of small molecules targeting Raf-1 kinase. Curr. Pharm. Des. 2002, 8, 2269-2278.
12. Lee, J. T.; McCubrey, J. A. BAY 43-9006 Bayer/Onix. Curr. Opin. Investig. Drugs 2003, 4, 757-763.
13. Batt, D. B.; Bold, G.; Kim, S.; Ramsey, T. M,; Sabio, M. L. Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases; Novartis AG: Switzerland, 2004; p 85.
14. Fink, C. A.; Perez, L. B.; Ramsey, T. M.; Yusuf, N.; Versace, R. W. et al. 1,4-Disubstituted isoquinoline derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases; Novartis AG.: Switzerland, 2005; p 144.
15. Ahmad, T.; Eisen, T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 2004, 10, 6388S-6392S.
16. Kotha, S.; Lahiri, K.; khashinath, D. Recent applications of the Suzuki-Miyaura cross coupling reactions in organic synthesis. Tetrahedron 2002, 58, 9633-9695.
17. Littke, A.; Fu, G. C. Palladium catalysed coupling reaction of aryl chlorides. Angew. Chem., Int. Ed. 2002, 41, 4176-4211.
18. Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. Simple, efficient catalyst system for the palladium-catalyzed amination of aryl chlorides, bromides and triflates. J. Org. Chem. 2000, 65, 1158-1174.
19. Grasa, G. A.; Viciu, M. S.; Huang, J.; Nolan, S. P. Amination reaction of aryl halides with nitrogen-containing reagents mediated by palladium/ imidazolium salts. J. Org. Chem. 2001, 66, 7729-7737.
20. Ghosh, A.; Sieser, J. E.; Riou, M.; Cai, W.; Rivera-Ruiz, L. Palladium-catalyzed synthesis of N-aryloxazolidinones from aryl chloride. Org. Lett. 2003, 5, 2207-2210.